Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment r...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Sangho Nam, MD, Sun Min Lim, MD, PhD, Byoung Chul Cho, MD, PhD, Jii Bum Lee, MD
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Elsevier 2024-02-01
Seri Bilgileri:JTO Clinical and Research Reports
Konular:
Trastuzumab deruxtecan
Interstitial lung disease
ERBB2 Y772-A775
Non–small cell lung cancer
Case report
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2666364323001716
Diğer Bilgiler
Özet:Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring HER2 mutations. Nevertheless, drug-induced interstitial lung disease (ILD)/pneumonitis is a concern that limits treatment response in this subset of patients. For grade 2 or more ILD/pneumonitis, permanent discontinuation is warranted with vigorous treatment with high-dose steroid. We report a case of successful rechallenge of trastuzumab deruxtecan after recovery of grade 3 ILD/pneumonitis in treatment-refractory NSCLC harboring ERBB2 Y772-A775dup.
ISSN:2666-3643

Benzer Materyaller